Home Newsfeeds Cowen & Co. Maintains Outperform on Match Group, Lowers Price Target to $128

Cowen & Co. Maintains Outperform on Match Group, Lowers Price Target to $128

Cowen & Co. analyst John Blackledge maintains Match Group (NASDAQ:MTCH) with a Outperform and lowers the price target from $130 to $128.

byBenzinga Newsdesk

July 26, 2022

1 minute read

Cowen & Co. analyst John Blackledge maintains Match Group (NASDAQ:MTCH) with a Outperform and lowers the price target from $130 to $128.

Why BofA Is Still Bullish On Microsoft Ahead Of Q2 Earnings

By Priya Nigam

July 18, 12:03 PM

Microsoft Corporation (NASDAQ: MSFT) is scheduled to report its fiscal fourth-quarter results on July 26.

MSFT

UK Might Be Next To Mull Over Ozempic’s ‘Miracle’ Weight Loss Solution, Popularized By Kim Kardashian And Chelsea Handler

By Benzinga Newsbot

July 10, 10:49 PM

The weight-loss drug Ozempic, popularized in the U.S. by celebrities such as Kim Kardashian and Chelsea Handler, is…

NVO

Magic Comes At A Price – Disneyland Raises Prices Up To 9%: Report

By Shivani Kumaresan

October 11, 12:47 PM

Walt Disney Company (NYSE: DIS) is reportedly implementing a price hike at its Disneyland venues, raising the stakes for visitors.

DIS

aTyr Pharma Presents Poster Demonstrating Preclinical Effects Of Efzofitimod In Rheumatoid Arthritis And Rheumatoid Arthritis-Associated ILD At The ACR Convergence 2023

By Benzinga Newsdesk

November 13, 9:28 AM

aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster

LIFE

Cowen & Co. Maintains Outperform on Match Group, Lowers Price Target to $128

Related Posts

Why BofA Is Still Bullish On Microsoft Ahead Of Q2 Earnings

UK Might Be Next To Mull Over Ozempic’s ‘Miracle’ Weight Loss Solution, Popularized By Kim Kardashian And Chelsea Handler

Magic Comes At A Price – Disneyland Raises Prices Up To 9%: Report

aTyr Pharma Presents Poster Demonstrating Preclinical Effects Of Efzofitimod In Rheumatoid Arthritis And Rheumatoid Arthritis-Associated ILD At The ACR Convergence 2023